PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Glioblastoma

Drugs in development · updated 30 October 2026

Glioblastoma: drugs in development

Rare diseasePrevalence 1-9 / 100 000 according to Orphanet · ORPHA:360

As of 30 October 2026 there are 289 active clinical trials (recruiting or ongoing, phases I–III) on 245 drugs for glioblastoma. 131 are experimental, that is not yet approved in the United States.

289Active trials
131Experimental drugs
13Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
ADI-PEG 20II–III3NCT03970447
AZD1390II–III3NCT03970447
VebreltinibPLB1001, APL-101II–III3NCT06105619
PaxalisibGDC-0084II–III2NCT03970447
TroriluzoleBHV-4157, Dazluma®II–III2NCT03970447
VeliparibABT-888II–III2NCT02152982
DenifanstatTVB-2640, ASC40 tabletsIII1NCT05118776
LAM561II–III1NCT04250922
MicrobubbleIII1NCT06496971
SafusidenibIII1NCT05303519
TinostamustineII–III1NCT03970447
VAL-083II–III1NCT03970447
VT1021II–III1NCT03970447
ACT001I–II2NCT05053880
AnlotinibAL3818, AnrotinibI–II2NCT07811297
AzeliragonTTP488II2NCT05986851
IndoximodII2NCT04049669
M032I–II2NCT05084430
MT-125I–II2NCT07604285
Onfekafusp alfaL19TNFI–II2NCT04443010
SilevertinibBDTX-1535II2NCT07326566
SintilimabSinitilimab, SindilimabII2NCT07670026
AdebrelimabSHR-1316, AdebelimabII1NCT07789379
AL58805I–II1NCT07811297
APG-157I–II1NCT06011109
BalstilimabBalstililmab, BalstilmabII1NCT05864534
BAY 3713372I–II1NCT06914128
BerubicinII1NCT04762069
BotensilimabII1NCT05864534
CC-115II1NCT02977780
CD141I–II1NCT03233152
CediranibZemfirza®II1NCT02974621
ChlorophyllinSodium Copper ChlorophyllinII1NCT06016452
CobolimabTSR-022I–II1NCT06521567
CTX-009I–II1NCT07392957
CTX-471I–II1NCT07392957
DichloroacetateII1NCT05120284
DOC1021II1NCT06805305
EBNK-001I–II1NCT07410676
Efineptakin alfaNT-I7, rhIL-7-hyFcII1NCT05465954

Sorted by most advanced phase and number of active trials. Showing 40 of 131 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
TemozolomideTemodal, TemodarII–III97NCT02152982
Bevacizumabavastin, MVASIIII20NCT06496971
PembrolizumabKEYTRUDA, MK-3475III19NCT06556563
LomustineCCNU, Gleostine®II–III12NCT03970447
CarboplatinCarboplatine, ParaplatinIII6NCT05902169
EtoposideAvopef®, Etopophos Preservative Free®II–III5NCT06105619
NiraparibZejula®III3NCT06388733
CisplatinCis Platinum, CisplatineII–III2NCT06105619
FerumoxytolFerabright®, Feraheme®III2NCT07461948
RegorafenibRegorafinib, BAY73-4506II–III2NCT03970447
NivolumabOpdivo, ONO-4538I–II14NCT06047379
CyclophosphamideCyclophosphamid, CytoxanI–II9NCT07523529
IpilimumabYERVOY, ipililumab IVI–II8NCT06047379
AtezolizumabTecentriq, MPDL3280AI–II7NCT05039281
FludarabineFludara, FLUDARABINI–II6NCT07523529

Sorted by most advanced phase and number of active trials. Showing 15 of 114 drugs.

All 245 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D005909 “Glioblastoma”. Prevalence: Orphanet.

ItalianoFrançaisDeutsch